Morphology-Associated Clock Audit

First deliverable: an auditable decision.

Start with the 2025 single-donor source. Reconcile Figure 5 with the main text. Obtain the supplement and authorized sample-level data; identify algorithms, versions, preprocessing and nested replicates. Preserve unknowns until verified. Compare matched handling/time and appropriate 2D/3D contexts; keep clocks and functional outcomes separate.

Deliver a source matrix, data dictionary, donor/batch/sample map, analysis assumptions, unresolved questions and a readable decision memo. No experiment, funding, staff appointment or laboratory access is claimed.

High-level study requirements.

• Use independent donors as the replication level for donor-generalizable claims; technical repeats remain nested.
• Match handling and observation time; justify relevant 2D, 3D and tissue comparators without treating them as equivalent.
• Prespecify a primary functional endpoint, meaningful effect criterion and missing-data rules. Use blinded analysis and record exclusions.
• Measure cell composition and identity, viability, senescence and adverse changes separately.
• Define durability after the initial observation or exposure; an early marker shift is insufficient.
• Later laboratory work requires separate scientific, safety, ethics where applicable, sourcing and rights review. This is not a cell-culture or treatment protocol.

Advance, revise or stop.

Do not infer rejuvenation from the current aggregate record. Advance to a reproducible reanalysis only when the discrepancy, clock implementation and sample map are resolved. Seek independent donors for generalization; report null, discordant and adverse outcomes. Retain an unresolved conclusion when essential evidence is unavailable.

Review prior art and rights before developing an implementation. Patentability, ownership, licensing and freedom to operate are separate, unresolved questions. The broad idea of antiaging/pro-regenerative screening is already described in WO2026035859A1; it is not presented as new Karam IP. A patent-database status label does not grant permission.

Existing routes to a scoped engagement.

Proposed scopes only. Qualified scientific review, authorized data, usable rights, capacity and written terms must be established before an engagement. No staff, customers, laboratory capacity or prices are asserted here.